RecruitingNCT06445322
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Studying Stargardt disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ascidian Therapeutics, Inc
- Principal Investigator
- Alia RashidAscidian Therapeutics
- Intervention
- Prescreening Assessments(diagnostic_test)
- Enrollment
- 50 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2024 – 2030
Study locations (8)
- University of San Francisco, San Francisco, California, United States
- Vitreo Retinal Associates, Gainesville, Florida, United States
- Wilmer Eye Institute at John Hopkins, Baltimore, Maryland, United States
- Massachusetts Eye and Ear, Boston, Massachusetts, United States
- University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- Retina Foundation of Texas, Dallas, Texas, United States
- Retina Consultants of Texas, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06445322 on ClinicalTrials.govOther trials for Stargardt disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425574A Study to Learn How Stargardt-type Eye Conditions Progress in Children and AdultsAstellas Pharma Global Development, Inc.
- RECRUITINGPHASE1, PHASE2NCT07439887Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt DiseaseRay Therapeutics, Inc.
- RECRUITINGPHASE1NCT07417566A Study of DC6001 Tablet in Healthy Chinese Adult SubjectsHeronova Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07161544A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)AAVantgarde Bio Srl
- RECRUITINGPHASE1, PHASE2NCT06942572A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)Splice Bio
- RECRUITINGPHASE1, PHASE2NCT06467344Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)Ascidian Therapeutics, Inc
- RECRUITINGNCT06591806An Observational Study in Children and Adults With Stargardt DiseaseAAVantgarde Bio Srl
- RECRUITINGNCT06435000An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 GeneSplice Bio